Softgel Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Softgel Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $11.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Softgel Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $11.5M Trade | TransData Nexus

Softgel Healthcare Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $11.5M Total Trade · DGFT Verified

Softgel Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $11.5M across 6 products in 4 therapeutic categories. Based on 238 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Vitamin ($6.8M), Acetaminophen ($2.1M), Dextromethorphan ($1.1M).

Softgel Healthcare Private Limited — Export Portfolio & Destination Treemap

Softgel Healthcare Private Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Softgel Healthcare Private Limited? — Company Overview & Market Position

Softgel Healthcare Private Limited, established on October 23, 2003, is a privately held pharmaceutical company headquartered in Pudupakkam, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24231TN2003PTC051829 and is classified as a non-government company. As of the latest available data, Softgel Healthcare has an authorized share capital of ₹40 crore and a paid-up capital of ₹29.96 crore. The company's registered office is located at Survey No. 20/1, Vandalur – Kelambakkam Road, Pudupakkam Village, Chengalpattu District, Tamil Nadu, India – 603103.

Softgel Healthcare specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. The company's product portfolio is concentrated, with the top five products accounting for 99.6% of its total export value. In the fiscal year 2022-2026, the company reported a total export value of $11.5 million USD from 238 shipments, exporting six products across four therapeutic categories. The top five products by export value are Vitamin ($6.8 million, 4.8% market share), Acetaminophen ($2.1 million, 0.9% market share), Dextromethorphan ($1.1 million, 7.4% market share), Phenylephrine ($1.1 million, 1.2% market share), and Omega ($316,000, 1.7% market share).

What Does Softgel Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vitamin

Product Portfolio — Top 6 by Export Value

Softgel Healthcare Private Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vitamin	Nutritional Supplements	$6.8M	137	4.8%	3
2	Acetaminophen	Analgesics & Antipyretics	$2.1M	43	0.9%	9
3	Dextromethorphan	Respiratory & OTC	$1.1M	22	7.4%	2
4	Phenylephrine	Respiratory & OTC	$1.1M	21	1.2%	12
5	Omega	Nutritional Supplements	$316.3K	11	1.7%	6
6	Docusate	Gastrointestinal	$48.9K	4	0.5%	10

Softgel Healthcare Private Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $11.5M. The top category is Nutritional Supplements (62.2% of portfolio), followed by Analgesics & Antipyretics (18.7%), indicating a concentrated portfolio with the top 5 products accounting for 99.6% of total export value.

Softgel Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Softgel Healthcare operates a manufacturing facility located at Survey No. 20/1, Vandalur – Kelambakkam Road, Pudupakkam Village, Chengalpattu District, Tamil Nadu, India – 603103. The facility is equipped to produce a range of pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing capabilities are supported by a dedicated Research & Innovation Centre (SRIC), inaugurated on February 5, 2026, at the Crescent Innovation and Incubation Council (CIIC), BSA Crescent Institute of Science and Technology, Chennai. The SRIC is designed to accelerate research and development across complex dosage forms, high-potent formulations, and differentiated delivery platforms, enabling faster and more reliable translation from concept to market.

3Key Leadership

As of April 2025, the key leadership at Softgel Healthcare includes:

Surendra Kumar Polavarapu: Chief Executive Officer (CEO), appointed on April 3, 2025.

Vishal Sharma: Director, appointed on September 12, 2022.

Arjun Oberoi: Director, appointed on September 12, 2022.

Sulaiman Abdulhai Mohammed: Director, appointed on September 12, 2022.

Jaipal Singh Bhagavan Singh: Whole-Time Director, appointed on August 7, 2021.

Puncham Mukim: Director, appointed on September 12, 2022.

These leaders are responsible for steering the company's strategic direction and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Softgel Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Softgel Healthcare has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for several of its products, such as Acetaminophen, Dextromethorphan Hydrobromide, and Doxylamine Succinate, which are listed in the FDA's database as of January 29, 2026. This indicates that Softgel Healthcare's products are accessible in the U.S. market. Additionally, the company's product portfolio includes items like Enzalutamide, Cyclosporine, Tafamidis, Nintedanib, and Ibuprofen, which are commonly used in various therapeutic areas and are subject to regulatory approvals in these markets. (fda.report)

While specific details regarding approvals in the European Union, United Kingdom, Australia, and Japan are not explicitly available, the company's focus on obtaining necessary certifications and approvals suggests a strategic approach to entering these markets. The establishment of the Research & Innovation Centre (SRIC) in February 2026 underscores Softgel Healthcare's commitment to enhancing its product development capabilities, which is crucial for meeting the stringent regulatory requirements of these regions.

2Emerging Markets

Softgel Healthcare has demonstrated a proactive approach in penetrating emerging markets across Africa, Latin America, and Southeast Asia. The company's product portfolio includes a range of over-the-counter (OTC) medications and nutritional supplements, which are in demand in these regions. For instance, products like Acetaminophen, Dextromethorphan, and Phenylephrine are commonly used for pain relief and cough management, aligning with the healthcare needs of these markets.

Softgel Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Softgel Healthcare has made notable progress in obtaining approvals from the U.S. Food and Drug Administration (FDA). As of January 29, 2026, the FDA's database lists several of the company's products, including Acetaminophen, Dextromethorphan Hydrobromide, and Doxylamine Succinate, indicating that these products are authorized for sale in the U.S. market. (fda.report)

The company's commitment to meeting FDA standards is further demonstrated by its active engagement in the regulatory process, with multiple product listings in the FDA's database. This proactive approach not only facilitates market entry but also underscores Softgel Healthcare's dedication to quality and compliance with international regulatory requirements. (fda.report)

2WHO & EU GMP

While specific details regarding the World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) certifications are not explicitly available, Softgel Healthcare's focus on obtaining necessary certifications and approvals suggests a strategic approach to entering these markets. The establishment of the Research & Innovation Centre (SRIC) in February 2026 underscores Softgel Healthcare's commitment to enhancing its product development capabilities, which is crucial for meeting the stringent regulatory requirements of these regions.

Softgel Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Softgel Healthcare operates in a competitive pharmaceutical market, with several key players offering similar products and services. Competitors include WuXi AppTec, Eurofins Scientific,

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Softgel Healthcare Private Limited

How many pharmaceutical products does Softgel Healthcare Private Limited export from India?

Softgel Healthcare Private Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Vitamin ($6.8M), Acetaminophen ($2.1M), Dextromethorphan ($1.1M), Phenylephrine ($1.1M), Omega ($316.3K). Total export value is $11.5M.

What is Softgel Healthcare Private Limited's total pharmaceutical export value?

Softgel Healthcare Private Limited's total pharmaceutical export value is $11.5M, based on 238 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Softgel Healthcare Private Limited cover?

Softgel Healthcare Private Limited exports across 4 therapeutic categories. The largest are Nutritional Supplements (62.2%, 2 products), Analgesics & Antipyretics (18.7%, 1 products), Respiratory & OTC (18.7%, 2 products).

Get Full Softgel Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.